EE05180B1 - Asaindooli sisaldav farmatseutiline kompositsioon raviotstarbeliseks kasutamiseks, asaindoolid ning nende kasutamine ravimite valmistamiseks, mis on ette n„htud proteiinikinaasi kataltilise toime p„rssimiseks - Google Patents

Asaindooli sisaldav farmatseutiline kompositsioon raviotstarbeliseks kasutamiseks, asaindoolid ning nende kasutamine ravimite valmistamiseks, mis on ette n„htud proteiinikinaasi kataltilise toime p„rssimiseks

Info

Publication number
EE05180B1
EE05180B1 EEP200200343A EEP200200343A EE05180B1 EE 05180 B1 EE05180 B1 EE 05180B1 EE P200200343 A EEP200200343 A EE P200200343A EE P200200343 A EEP200200343 A EE P200200343A EE 05180 B1 EE05180 B1 EE 05180B1
Authority
EE
Estonia
Prior art keywords
azaindoles
medicament
inhibiting
manufacture
pharmaceutical composition
Prior art date
Application number
EEP200200343A
Other languages
English (en)
Estonian (et)
Inventor
Joseph Cox Paul
Nadeem Majid Tahir
Yeun Quai Lai Justine
David Morley Andrew
Amendola Shelley
Deprets Stephanie
Edlin Chris
Original Assignee
Aventis Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930698.7A external-priority patent/GB9930698D0/en
Application filed by Aventis Pharma Limited filed Critical Aventis Pharma Limited
Publication of EE200200343A publication Critical patent/EE200200343A/xx
Publication of EE05180B1 publication Critical patent/EE05180B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
EEP200200343A 1999-12-24 2000-12-27 Asaindooli sisaldav farmatseutiline kompositsioon raviotstarbeliseks kasutamiseks, asaindoolid ning nende kasutamine ravimite valmistamiseks, mis on ette n„htud proteiinikinaasi kataltilise toime p„rssimiseks EE05180B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930698.7A GB9930698D0 (en) 1999-12-24 1999-12-24 Chemical compounds
US21581800P 2000-07-05 2000-07-05
PCT/GB2000/004993 WO2001047922A2 (fr) 1999-12-24 2000-12-27 Azaindoles

Publications (2)

Publication Number Publication Date
EE200200343A EE200200343A (et) 2003-06-16
EE05180B1 true EE05180B1 (et) 2009-06-15

Family

ID=26316153

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200343A EE05180B1 (et) 1999-12-24 2000-12-27 Asaindooli sisaldav farmatseutiline kompositsioon raviotstarbeliseks kasutamiseks, asaindoolid ning nende kasutamine ravimite valmistamiseks, mis on ette n„htud proteiinikinaasi kataltilise toime p„rssimiseks

Country Status (27)

Country Link
US (2) US6770643B2 (fr)
EP (2) EP1990343B1 (fr)
JP (1) JP5436507B2 (fr)
KR (2) KR100755622B1 (fr)
CN (2) CN100379734C (fr)
AP (2) AP1917A (fr)
AU (1) AU777717B2 (fr)
BG (2) BG66066B1 (fr)
BR (1) BR0017038A (fr)
CA (2) CA2395593C (fr)
CY (1) CY1110951T1 (fr)
CZ (2) CZ301751B6 (fr)
DZ (1) DZ3377A1 (fr)
EA (1) EA005212B1 (fr)
EE (1) EE05180B1 (fr)
HK (1) HK1050191B (fr)
HR (1) HRP20020547B1 (fr)
HU (1) HUP0203895A3 (fr)
IL (3) IL150388A0 (fr)
MA (1) MA26857A1 (fr)
MX (1) MXPA02006338A (fr)
NO (2) NO323766B1 (fr)
NZ (1) NZ519121A (fr)
OA (1) OA12514A (fr)
PL (1) PL209572B1 (fr)
SK (2) SK287882B6 (fr)
WO (1) WO2001047922A2 (fr)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2679459B2 (ja) 1991-08-02 1997-11-19 王子製紙株式会社 感熱記録体
HUP0203895A3 (en) 1999-12-24 2004-09-28 Aventis Pharma Ltd West Mallin Substituted azaindoles and pharmaceutical compositions containing them and their use
PL364279A1 (en) * 2001-02-02 2004-12-13 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (fr) * 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthese de composes heterocycliques faisant appel a une technologie micro-onde
EP2335700A1 (fr) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
US6884889B2 (en) * 2002-03-25 2005-04-26 Bristol-Myers Squibb Co. Processes for the preparation of antiviral 7-azaindole derivatives
EP1490365B1 (fr) * 2002-03-28 2010-02-10 Eisai R&D Management Co., Ltd. Azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n
KR20040111445A (ko) * 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
US20050124620A1 (en) * 2002-04-09 2005-06-09 Martyn Frederickson Pharmaceutical compounds
EP1495016A2 (fr) * 2002-04-09 2005-01-12 Astex Technology Limited Composes heterocycliques et leur utilisation comme modulateurs de la kinase p38 map
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
EP1388541A1 (fr) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines utilisées comme inhibiteurs de kinases
US7186716B2 (en) 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
SE0202464D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
US7186725B2 (en) * 2003-01-03 2007-03-06 Genzyme Corporation Anti-inflammatory compositions and methods
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7432375B2 (en) * 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
SE0300908D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301372D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
US7612086B2 (en) 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
BRPI0412684A (pt) 2003-07-17 2006-10-03 Plexxinko Inc compostos ppar-ativos
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN1922174A (zh) 2004-02-20 2007-02-28 贝林格尔·英格海姆国际有限公司 病毒聚合酶抑制剂
FR2868422B1 (fr) 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2005105788A1 (fr) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Derives d'indole et leur utilisation en tant qu'inhibiteurs de kinases
WO2006023931A2 (fr) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Inhibiteurs de kinase
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1812439B2 (fr) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1833829A2 (fr) * 2004-12-23 2007-09-19 F. Hoffmann-Roche AG Imidazo- et pyrrolo-pyridines à substitution benzamide comme inhibiteurs de protéine kinase
CA2589877A1 (fr) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Derives carbamates heterocycliques, leur fabrication et leur utilisation comme agents pharmaceutiques
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
JP2008545660A (ja) 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
JP5071374B2 (ja) * 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
CA2618682C (fr) * 2005-08-12 2011-06-21 Boehringer Ingelheim International Gmbh Inhibiteurs de polymerase virale
WO2007038215A1 (fr) * 2005-09-22 2007-04-05 Incyte Corporation Inhibiteurs tetracycliques de janus kinases
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007067537A1 (fr) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Composés inhibant les pyrrolopyridine kinases
HUE028588T2 (hu) * 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
WO2007076348A2 (fr) * 2005-12-23 2007-07-05 Smithkline Beecham Corporation Inhibiteurs azaindoliques des kinases aurora
WO2007084667A2 (fr) * 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Inhibiteurs de kinase heterobicycliques fusionnes
US8604031B2 (en) * 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
US7741360B2 (en) 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
WO2008014249A2 (fr) * 2006-07-24 2008-01-31 Sanofi-Aventis Préparation améliorée de composés d'azaindole
GB0617161D0 (en) * 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
EP2223925A1 (fr) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
ES2415863T3 (es) * 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
EP2740731B1 (fr) * 2007-06-13 2016-03-23 Incyte Holdings Corporation Sels cristallines de l'inhibiteur de janus kinase (r)-3-(4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl) -3-cyclopentylpropanenitrile
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EA020777B1 (ru) * 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
CN101952295B (zh) 2008-02-25 2013-11-20 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
ATE517107T1 (de) * 2008-02-25 2011-08-15 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitoren
ATE522536T1 (de) 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
ATE519763T1 (de) 2008-02-25 2011-08-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
RU2503676C2 (ru) 2008-02-25 2014-01-10 Ф.Хоффманн-Ля Рош Аг Пирролопиразиновые ингибиторы киназы
AU2009223501A1 (en) * 2008-03-10 2009-09-17 Sanofi-Aventis Treatment for ocular-related disorders
MY165582A (en) * 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
CA2722326A1 (fr) * 2008-04-24 2009-10-29 Incyte Corporation Composes macrocycliques et leur utilisation a titre d'inhibiteurs de kinase
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010046215A2 (fr) * 2008-10-21 2010-04-29 Syngenta Participations Ag Dérivés de diazaindole et leur emploi en tant que fongicides
US8765727B2 (en) * 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
NZ596479A (en) * 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
BRPI1012108B8 (pt) 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
CN102471345A (zh) * 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡嗪抑制剂
JP2013503132A (ja) 2009-08-26 2013-01-31 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング メチルピロロピリジンカルボキサミド
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
EP2338890A1 (fr) 2009-12-22 2011-06-29 Bayer CropScience AG Dérivés de 4,7-diazaindole et leur utilisation en tant que fongicides
US20110207754A1 (en) * 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
WO2011109932A1 (fr) * 2010-03-09 2011-09-15 F.Hoffmann-La Roche Ag Nouveau procédé pour la fabrication de 7-azaindoles 5-halogénés
CA2792508C (fr) 2010-03-10 2018-01-16 Incyte Corporation Derives de piperidin-4-yl azetidine en tant qu'inhibiteurs de jak1
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
MX2012013194A (es) 2010-05-20 2013-01-22 Hoffmann La Roche Derivados pirrolopirazinas como inhibidores de cinasas tirocina-cinasa del baso (syk) y cinasa de janus (jak).
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
CA2818542A1 (fr) 2010-11-19 2012-05-24 Incyte Corporation Derives pyrrolopyridine et pyrrolopyrimidine a substitution cyclobutyle utilises comme inhibiteurs des jak
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
WO2012112847A1 (fr) 2011-02-18 2012-08-23 Novartis Pharma Ag Plurithérapie impliquant un inhibiteur de mtor et un inhibiteur de jak
AU2012253885A1 (en) 2011-05-10 2013-10-31 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
WO2012154518A1 (fr) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines en tant qu'inhibiteurs de syk
CA2834062A1 (fr) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridylaminopyridines en tant qu'inhibiteurs de syk
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
WO2013023119A1 (fr) 2011-08-10 2013-02-14 Novartis Pharma Ag Polythérapie par jak p13k/mtor
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
EP2763976B1 (fr) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 2-pyridyl carboxamide
WO2013052391A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide
ES2606638T3 (es) * 2012-02-21 2017-03-24 Merck Patent Gmbh Derivados de furopiridina
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2863913B1 (fr) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Analogues d'imidazolyle en tant qu'inhibiteurs de syk
WO2013192125A1 (fr) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Dérivés de pyrazolyle en tant qu'inhibiteurs de syk
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
WO2013192088A1 (fr) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique (syk) diazines et triazines substituées
RU2611010C2 (ru) 2012-07-26 2017-02-17 Глаксо Груп Лимитед 2-(Азаиндол-2-ил)бензимидазолы в качестве ингибиторов PAD4
EP2884982B1 (fr) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
WO2014048065A1 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Dérivés triazolyle en tant qu'inhibiteurs de la syk
KR102242077B1 (ko) 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
EP3489239B1 (fr) 2013-03-06 2021-09-15 Incyte Holdings Corporation Procédés et intermédiaires pour fabriquer un inhibiteur de jak
MX2015012899A (es) 2013-03-14 2016-06-02 Abbvie Inc Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9.
TW201446763A (zh) * 2013-03-14 2014-12-16 Abbvie Inc 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
CN105073747B (zh) * 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
MX376856B (es) 2013-08-07 2025-03-07 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
WO2015184305A1 (fr) 2014-05-30 2015-12-03 Incyte Corporation Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1
AU2015360360B2 (en) * 2014-12-11 2020-06-25 Beta Pharma (Shanghai) Co., Ltd. Substituted 2-anilinopyrimidine derivatives as EGFR modulators
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US20200071326A1 (en) * 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
WO2018226846A1 (fr) 2017-06-07 2018-12-13 Plexxikon Inc. Composés et procédés de modulation de kinase
SG11201911859QA (en) 2017-06-16 2020-01-30 Beta Pharma Inc Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
MD3746429T2 (ro) 2018-01-30 2022-08-31 Incyte Corp Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
KR20260080448A (ko) 2018-03-30 2026-06-02 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
CA3129665A1 (fr) 2019-03-21 2020-09-24 Onxeo Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
TW202131926A (zh) 2019-11-22 2021-09-01 美商英塞特公司 包含alk2抑制劑及jak2抑制劑的組合療法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR102818206B1 (ko) * 2021-07-12 2025-06-11 한양대학교 에리카산학협력단 인다졸일 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB966264A (en) 1961-08-31 1964-08-06 Distillers Co Yeast Ltd Production of alkyl pyridines
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) * 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
EP0405602A1 (fr) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. Dérivés zinciques de substances antiiflammatoires doués d'une activité thérapeutique améliorée
US5202108A (en) * 1990-10-12 1993-04-13 Analytical Development Corporation Process for producing ferrate employing beta-ferric oxide
SE9100920D0 (sv) * 1991-03-27 1991-03-27 Astra Ab New active compounds
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JP3119758B2 (ja) 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6075037A (en) * 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
GB2298199A (en) 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
AR007855A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
US5783969A (en) 1996-09-04 1998-07-21 Motorola, Inc. Method and system for preventing an amplifier overload condition in a hybrid matrix amplifier array
HUP9903330A2 (hu) * 1996-11-19 2000-03-28 Amgen Inc. Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények
GB9708235D0 (en) * 1997-04-23 1997-06-11 Ciba Geigy Ag Organic compounds
WO1998047899A1 (fr) * 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Pyrrolopyridines substituees utilisees dans le traitement des maladies inflammatoires
WO1999007703A1 (fr) * 1997-08-05 1999-02-18 Pfizer Products Inc. 4-AMINOPYRROLE(3,2-d)PYRIMIDINES EN TANT QU'ANTAGONISTES DU RECEPTEUR DU NEUROPEPTIDE Y
HRP20000209A2 (en) * 1997-10-20 2001-04-30 Hoffmann La Roche Bicyclic kinase inhibitors
WO1999051595A1 (fr) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
CA2325995A1 (fr) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
WO1999051234A1 (fr) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonistes de la gonadoliberine
AU3210799A (en) * 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP1067930A4 (fr) 1998-04-02 2002-09-18 Merck & Co Inc Antagonistes de l'hormone liberant la gonadotropine (gnrh)
US6025366A (en) 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999058518A2 (fr) 1998-05-12 1999-11-18 American Home Products Corporation Acides biphenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
ATE482945T1 (de) 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ439199A3 (cs) * 1998-07-10 2000-07-12 Pfizer Products Inc. 4-Aminopyrrol(3^-d)pyrimidiny jako antagonisty receptoru neuropeptidu Y
CZ2001959A3 (cs) * 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidiny jako inhibitory kinasy
PT1144367E (pt) 1998-12-31 2004-12-31 Aventis Pharma Inc Substituicao alfa de compostos de ester beta-amido nao protegidos
CA2375843A1 (fr) 1999-06-04 2000-12-14 Qi Zhao Compositions et methodes permettant d'inhiber la mort cellulaire
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
DE19944051A1 (de) 1999-09-14 2001-03-15 Wilke Heinrich Hewi Gmbh Verriegelungsvorrichtung
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
HUP0203895A3 (en) 1999-12-24 2004-09-28 Aventis Pharma Ltd West Mallin Substituted azaindoles and pharmaceutical compositions containing them and their use
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
US6264966B1 (en) 2000-02-22 2001-07-24 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
AU778417B2 (en) 2000-02-25 2004-12-02 Merck & Co., Inc. Tyrosine kinase inhibitors
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
GB0007657D0 (en) 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
US6673923B2 (en) * 2000-05-03 2004-01-06 Tularik Inc. Pyrazole antimicrobial agents
MXPA02010763A (es) 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds

Also Published As

Publication number Publication date
AU2209401A (en) 2001-07-09
AP1917A (en) 2008-11-12
OA12514A (en) 2006-05-29
KR100910488B1 (ko) 2009-08-04
SK9012002A3 (en) 2003-04-01
NO323766B1 (no) 2007-07-02
AP2002002516A0 (en) 2002-06-30
IL150388A0 (en) 2002-12-01
PL209572B1 (pl) 2011-09-30
DZ3377A1 (fr) 2001-07-05
IL193615A0 (en) 2009-05-04
AU777717B2 (en) 2004-10-28
EP1263759B1 (fr) 2010-09-08
SK287882B6 (sk) 2012-02-03
NO330747B1 (no) 2011-07-04
CZ20022207A3 (cs) 2002-11-13
CA2699568A1 (fr) 2001-07-05
CY1110951T1 (el) 2015-06-11
NZ519121A (en) 2004-05-28
US20040198737A1 (en) 2004-10-07
MA26857A1 (fr) 2004-12-20
CA2395593A1 (fr) 2001-07-05
KR20070050103A (ko) 2007-05-14
IL150388A (en) 2010-11-30
JP5436507B2 (ja) 2014-03-05
CZ301750B6 (cs) 2010-06-09
BR0017038A (pt) 2003-01-07
JP2012031181A (ja) 2012-02-16
EP1990343B1 (fr) 2012-04-04
CN100379734C (zh) 2008-04-09
CZ301751B6 (cs) 2010-06-09
KR20020062663A (ko) 2002-07-26
HRP20020547B1 (hr) 2011-06-30
US7227020B2 (en) 2007-06-05
US20040009983A1 (en) 2004-01-15
BG66066B1 (bg) 2011-01-31
PL355819A1 (en) 2004-05-17
BG106836A (bg) 2003-04-30
EE200200343A (et) 2003-06-16
HUP0203895A3 (en) 2004-09-28
HUP0203895A2 (hu) 2003-02-28
NO20066017L (no) 2002-06-21
US6770643B2 (en) 2004-08-03
NO20023032D0 (no) 2002-06-21
AP2006003492A0 (en) 2006-02-28
WO2001047922A2 (fr) 2001-07-05
EP1263759A2 (fr) 2002-12-11
HRP20020547A2 (hr) 2005-10-31
CA2699568C (fr) 2013-03-12
NO20023032L (no) 2002-06-21
MXPA02006338A (es) 2002-12-13
AP1587A (en) 2006-03-02
EP1990343A2 (fr) 2008-11-12
EP1990343A3 (fr) 2008-12-10
HK1050191B (en) 2011-04-29
KR100755622B1 (ko) 2007-09-04
HK1050191A1 (en) 2003-06-13
EA200200707A1 (ru) 2003-02-27
EA005212B1 (ru) 2004-12-30
CN1615873A (zh) 2005-05-18
CN1413213A (zh) 2003-04-23
BG66176B1 (bg) 2011-11-30
BG110623A (bg) 2010-07-30
WO2001047922A3 (fr) 2002-01-17
SK288019B6 (sk) 2012-11-05
CA2395593C (fr) 2011-08-02

Similar Documents

Publication Publication Date Title
EE200200343A (et) Asaindooli sisaldav farmatseutiline kompositsioonraviotstarbeliseks kasutamiseks, asaindoolid ningnende kasutamine ravimite valmistamiseks, mis on ette nähtud proteiinikinaasi katalüütilise toime pärssimiseks
EE200300295A (et) Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
HUP0300602A3 (en) Diazabicyclic central nervous system active agents, pharmaceutical compositions containing them and their use
IL171683A (en) Immunosuppressive Compounds, Medicinal Products Containing Them and Their Use in the Preparation of Medication for Treatment
EE200200274A (et) Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
EP1068874A4 (fr) Distributeur de medicament du type inhalateur
NZ517659A (en) Pharmaceutical delivery system for enhanced absorption of hydrophilic therapeutic agents
PL357535A1 (en) Hydrogel-driven drug dosage form
SI0966454T1 (sl) Disubstituirani biciklični heterocikli, njihova priprava in uporaba kot zdravila
DK1204410T3 (da) Farmaceutisk doseringsform med flere komponenter
EE200000770A (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
HUP0402661A3 (en) Formulation and dosage form for the controlled delivery of therapeutic agents
NO20003218L (no) Oral farmasøytisk doseringsform med forlenget frigivningsvirkning
EE200200046A (et) 8-fenüül-6,9-dihüdro-[1,2,4]triasolo[3,4-i]puriin-5-ooni derivaat, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
EE05424B1 (et) Asendatud asaindooloksoatseetpiperasiini derivaadid, neid sisaldav ravimpreparaat ning nende kasutamine ravis
HUP0200155A3 (en) Thioamide derivatives, pharmaceutical compositions containing them and their use
EE05271B1 (et) 7-asaindoolid, meetod nende snteesimiseks, nende kasutamine TNFa v?i fosfodiesteraas-4 inhibeerivate ravimite valmistamiseks ning neid sisaldavad ravimid
HUP0302333A3 (en) The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE60301570D1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EE200100388A (et) Püridasino [4,5-b] indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite düsfunktsioneerimisega seotud haiguste raviks
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
EE05168B1 (et) N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
NO323466B1 (no) Nye kinolinyl-piperidin-4-yliden-metyl-benzamidderivater, fremgangsmate til fremstilling derav, anvendelse derav i medikamenter til behandling av smerte, samt farmasoytisk sammensetning som innbefatter slike derivater
NO20002526L (no) Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20141227